Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 31;12(1):e008233. doi: 10.1136/jitc-2023-008233

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Antineoplastic and immunomodulating agents associated with increased risk of postimmunization SARS-CoV-2 infection in a class dependent manner. (A) Cumulative incidence of SARS-CoV-2 infection following initial immunization in all patients receiving antineoplastic and immunomodulating agents (treatment, n=13 362) compared with matched control patients (n=13 362) (p<0.001 by log-rank). (B) Effect of multiple immunizations on SARS-CoV-2 infection incidence postimmunization (treatment: 2 immunizations n=3333, 3 immunizations n=5174, 4 immunizations n=4855; control: 2 immunizations n=3245, 3 immunizations n=5352, 4 immunizations n=4765) (p<0.001 by log-rank square). (C) SARS-CoV-2 infection cumulative incidence following initial immunization in all patients receiving L01: antineoplastic agents, patients receiving multiple medications excluded from analysis (L01 antineoplastic agent receiving patients n=4124) (p<0.0001 by log-rank). (D) SARS-CoV-2 infection cumulative incidence following initial immunization in all patients receiving L02: endocrine therapy, patients receiving multiple medications excluded from analysis (L02 endocrine therapy receiving patients n=2999) (p=0.7734 by log-rank). (E) SARS-CoV-2 infection cumulative incidence following initial immunization in all patients receiving L03: immunostimulants, patients receiving multiple medications excluded from analysis (L03 immunostimulant receiving patients n=94) (p=0.8548 by log-rank). (F) SARS-CoV-2 infection cumulative incidence following initial immunization in all patients L04: immunosuppressants, patients receiving multiple medications excluded from analysis (L04 immunosuppressant receiving patients n=3140) (p<0.0001 by log-rank). ATC, Anatomical Therapeutic Chemical.